Recombinant Anti-CD3 x Anti-IGF1R Bispecific Antibody (scFv-CH1/CL) (BSCC-092)

Recombinant Anti-CD3 x Anti-IGF1R Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CD3 antibody variable domain is fused to CH1 and the other scFv from an anti-IGF1R antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can retarget T cells to tumor cells. It is designed for the research of Melanoma; Colon cancer; Pancreas cancer; Prostate cancer; Kidney cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & IGF1R

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Melanoma; Colon cancer; Pancreas cancer; Prostate cancer; Kidney cancer

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

IGF1R

Gene ID

3480

UniProt ID

P08069

Alternative Names

IGF1R; insulin-like growth factor 1 receptor; IGFR; CD221; IGFIR; JTK13; IGF-I receptor; soluble IGF1R variant 1; soluble IGF1R variant 2; insulin-like growth factor I receptor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-IGF1R Bispecific Antibody (scFv-CH1/CL) (BSCC-092). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD3 x Anti-IGF1R Bispecific Antibody (scFv-CH1/CL) (CAT#: BSCC-092)

Specifications

Targets

Customer Reviews and Q&As